Skip to main content
. 2020 Mar 4;9(1):LMT28. doi: 10.2217/lmt-2019-0011

Figure 2. . Results of the main scenario: average cost per patient treated with alectinib versus crizotinib.

Figure 2. 

Annual cost per patient treated with crizotinib was higher than patients treated with alectinib (€12,575 vs €7627, respectively), which resulted in a cost difference of €4949.